No Data
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
On January 14, TRANSCENTA-B (06628) spent 0.0244 million Hong Kong dollars to repurchase 0.0405 million shares.
TRANSCENTA-B (06628) announced that on January 14, 2025, the company invested 0.0244 million Hong Kong dollars...
TRANSCENTA-B (06628.HK) repurchased 0.01 million shares on January 10.
Gelonghui January 10th丨TRANSCENTA-B (06628.HK) announced that on January 10th, it spent HKD 6,100 to repurchase 0.01 million shares.
TRANSCENTA-B (06628.HK) spent 0.06 million HKD to repurchase 0.1 million shares on January 9.
On January 9, Legend Holdings Group-B (06628.HK) announced that it spent 0.06 million Hong Kong dollars to repurchase 0.1 million shares.
TRANSCENTA-B (06628.HK) spent HKD 9,409.6 to repurchase 0.016 million shares on January 3.
Gelonghui, January 3rd丨TRANSCENTA-B (06628.HK) announced that on January 3rd, it spent 9,409.6 Hong Kong dollars to repurchase 0.016 million shares.
TRANSCENTA-B (06628.HK) spent 0.0902 million HKD to repurchase 0.147 million shares on December 31.
Gelonghui, on December 31, announced that TRANSCENTA-B (06628.HK) spent 0.0902 million HKD to repurchase 0.147 million shares, with a repurchase price ranging from 0.59 to 0.63 HKD per share.
